Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort

Arthritis Care and Research

Volumn 57, Issue 3, 2007, Pages 440-447

  Khanna, Dinesh ^a,e   Oh, Myungshin ^b   Furst, Daniel E ^b   Ranganath, Veena ^b   Gold, Richard H ^b   Sharp, John T ^c   Park, Grace S ^b   Keystone, Edward C ^d   Paulus, Harold E ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical remission; Low disease activity; Minimal disease activity; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DISEASE ACTIVITY; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; REMISSION; RHEUMATOID ARTHRITIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TERMINOLOGY;

EID: 34247568912     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.22619     Document Type: Article

References (19)

1. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
2. St.Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.
3. Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005;32:2016-24.
4. Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36.
5. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005;23 Suppl 39:S100-8.
6. Khanna D, Wu H, Park G, Gersuk V, Gold RH, Nepom GT, et al. Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. Arthritis Rheum 2006;54:1105-16.
7. Khanna D, Ranganath VK, FitzGerald J, Park GS, Altman RD, Elashoff D, et al. Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage. Arthritis Rheum 2005;52:2284-92.
8. Van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
9. Van der Heijde DM, van 't Hof MA, van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 1992;51:177-81.
10. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis: correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-20.
11. Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985;28:1326-35.
12. Prevoo ML, 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
13. Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;24:1308-15.
14. Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991.
15. Furst DE. Window of opportunity [editorial]. [published erratum appears in J Rheumatol 2004;31:2315-6]. J Rheumatol 2004;31:1677-9.
16. Quinn MA, Cox S. The evidence for early intervention. Rheum Dis Clin North Am 2005;31:575-89.
17. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21 Suppl 31:S154-7.
18. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis [editorial]. Arthritis Rheum 2003;48:1771-4.
19. Landewe R, van der Heijde DM, Voskuyl A, Boers M. Condensed 28-joint counts jeopardise the construct validity of DAS28-remission: a comparison with the original DAS [abstract]. Arthritis Rheum 2004;50:S457.